Joseph O. Moore - Concepedia

Author

Joseph O. Moore

Also Known As

B. Peterson, Beaven, Anne, J Moore, J O Moore, J. Miskimins, J. Moore, J. O. Moore, J.O Moore, J.O. Moore, James Wortman

234

Publications

11.3K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University Roswell Park Comprehensive Cancer Center Duke University Hospital University of Alabama at Birmingham

About

Joseph O. Moore is an author at Duke Medical Center specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	57	4.2K
2	Health Sciences	7	7	866
3	Public Health	4	4	285
4	Allergy	2	2	31
5	Biochemistry	2	2	49

Joseph O. Moore

111

Publications

10.8K

Citations

H-Index

Page 1

	Year	Citations
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia Robert J. Mayer, Roger B. Davis, Charles A. Schiffer, New England Journal of Medicine	1994	1.4K
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud, Journal of the National Comprehensive Cancer Network Hematological MalignancyVersion 3.2017OncologyHealth SciencesMixed-phenotype Acute Leukemia	2017	651
Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia Richard M. Stone, Deborah Berg, Stephen L. George, New England Journal of Medicine	1995	451
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered John C. Byrd, Richard K. Dodge, Andrew J. Carroll, Journal of Clinical Oncology	1999	312
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Isidore Tepler, Laurence Elias, John W. Smith, PubMed	1996	305
Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Susan O’Brien, Joseph O. Moore, Thomas E. Boyd, Journal of Clinical Oncology	2007	298
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology Jerald P. Radich, Michael W. Deininger, Camille N. Abboud, Journal of the National Comprehensive Cancer Network Hematological MalignancyChronic Myeloid LeukemiaMedicinePhiladelphia ChromosomeCancer Management	2018	281
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Journal of the National Comprehensive Cancer Network Hematological MalignancyChronic Myeloid LeukemiaMedicinePhiladelphia ChromosomeCancer Management	2020	264
Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia Eric J. Feldman, Joseph Brandwein, Richard M. Stone, Journal of Clinical Oncology	2005	248
Expression and prognostic impact of lncRNAs in acute myeloid leukemia Ramiro Garzon, Stefano Volinia, Dimitrios Papaioannou, Proceedings of the National Academy of Sciences	2014	229

Page 1